Belharra Therapeutics disrupts the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform.
Belharra Therapeutics has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
Belharra Therapeutics's investors include Versant Ventures.
Belharra Therapeutics is headquartered in San Diego, United States.
Belharra Therapeutics disrupts the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform.
Belharra Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Belharra Therapeutics — Funding & Investors." VCBacked, January 4, 2023, https://www.vcbacked.co/company/belharra-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Belharra Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/belharra-therapeutics
{{cite web |title=Belharra Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/belharra-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated